Hormone therapy study could unlock secrets of immune differences

NCT ID NCT07358897

Not yet recruiting Knowledge-focused Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 500 transgender adults starting gender-affirming hormone therapy to see how their immune systems change. By tracking immune cells and blood markers before and during treatment, researchers hope to understand why men and women have different rates of autoimmune diseases and infections. The goal is to learn how sex hormones alone—without the influence of chromosomes—shape immune function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gender-affirming hormone therapy (estrogen or testosterone)
What this could lead to: If successful, this study could reveal how sex hormones influence immune system differences, potentially guiding new treatments for autoimmune diseases and infections.
What could go wrong: This is an observational study that does not test a treatment, so it won't directly lead to new therapies. Results may not apply to non-transgender populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSGENDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSGENDER

More trials for these conditions

Other studies related to the condition(s) this trial covers.